These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29554386)

  • 1. Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.
    Jansen ME; Krambeer CJ; Kermany DS; Waters JN; Tie W; Bahadorani S; Singer J; Comstock JM; Wannamaker KW; Singer MA;
    Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):186-190. PubMed ID: 29554386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
    Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
    Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea.
    Nesmith BL; Ihnen M; Schaal S
    Retina; 2014 Dec; 34(12):2423-30. PubMed ID: 25062438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities.
    Achiron A; Lagstein O; Glick M; Gur Z; Bartov E; Burgansky-Eliash Z
    Acta Ophthalmol; 2015 Dec; 93(8):e649-53. PubMed ID: 25899144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Boiko EV; Maltsev DS
    Retina; 2018 Jul; 38(7):1324-1330. PubMed ID: 28492427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC; Brown DM; Payne JF; Wykoff CC
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.
    Hwang DJ; Lee EJ; Lee SY; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2014 May; 55(7):4213-9. PubMed ID: 24833740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel.
    Regillo CD; Callanan DG; Do DV; Fine HF; Holekamp NM; Kuppermann BD; Singer MA; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2017 Apr; 48(4):291-301. PubMed ID: 28419394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
    Nariani A; Williams B; Hariprasad SM
    Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
    Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
    Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
    Sonoda Y; Arimura N; Shimura M; Sakamoto T
    Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant Bilateral Response in Diabetic Macular Edema After Single Unilateral Intravitreal Aflibercept Injection.
    Rahimy E; Nyong'o O; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2017 Feb; 48(2):167-169. PubMed ID: 28195620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
    Seo KH; Yu SY; Kim M; Kwak HW
    Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.